21 November 2014
Below: Implementer Bloc Statement on Investing in Hepatitis C Treatment
1. The Board acknowledges the Strategy, Investment and Impact Committee's (the "SIIC") plan to develop recommendations for consideration at the March 2015 Board meeting on the Global Fund's role in funding treatment of co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria, and directs the Secretariat to engage and collaborate with partners to support the SIIC's development of such recommendations.
2. As an interim measure until there is an outcome to those deliberations, where there is a currently approved budget for Hepatitis C virus (HCV) treatment within an existing Global Fund grant, the Global Fund may continue to fund such a treatment up to approved budget amount, as set forth in GF/B32/22, and may otherwise permit continuation of Global Fund funded HCV treatment programs during this interim period with new grants in these countries up to previously approved budgeted levels.